Encore Vision president and CEO Bill Burns said: "We are pleased to confirm that 75 subjects have been enrolled in the study and to date, there have been
Data generated from the analysis are expected to expand the understanding of multiple myeloma biology and potentially identify mechanisms of sensitivity or resistance to proteasome inhibitor treatment, which
This will allow researchers to develop automated cancer detection image analysis tools which can be easily distributed to research and clinical users. The platform will also support the
BOTOX is the first and only botulinum toxin product to be approved by the FDA to treat multiple muscle groups of the upper (elbow, wrist, fingers, and thumb)
Dyax is engaged in the development and commercialization of novel biotherapeutics for unmet medical needs. The company is developing DX-2930, a fully humanized monoclonal antibody targeting plasma kallikrein
Based on this review, the DSMB observed a continued acceptable safety and tolerability profile of Pyridorin in patients with overt diabetic nephropathy. NephroGenex CEO and President Pierre Legault
Oxeia’s lead program, OXE-103, uniquely targets the metabolic injury and energy crisis underlying acute concussion pathology. OXE-103 restores mitochondrial homeostasis via a well-characterized mechanism of action and may
The strategic alliance combines the strength of Optum’s clinical data set derived from electronic health records (EHRs), claims data assets and analytics with PAREXEL’s global, site-based research experience.
The financing was co-led by existing investors Entrepreneurs Fund, Heidelberg Capital Private Equity and new investor, UK based Fort Rock Capital. Existing investors Bayern Kapital and funds advised
AST-VAC2 is an innovative immunotherapy product that contains mature dendritic cells derived from pluripotent stem cells. These non-patient specific (allogeneic) AST-VAC2 cells are engineered to express a modified
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.